Roche Pays US$7.1 B for Bowel Disease Drug from Roivant and Pfizer
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 27 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2828 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an attempt to boost its pipeline, Roche has agreed to acquire Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to US$7...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS